Kairo

The company is offering  shares at an expected price of $4.00 per share with an insider lock-up period of 180 days ending on March 11, 2025.

See also: Benzinga IPO Calendar

About Kairos Pharma, Ltd

Kairos Pharma, Ltd is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance.

See also: Benzinga's Most Shorted Stocks

This article was generated by Benzinga's automated content engine and reviewed by an editor.